Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-01 | Dr. Ornskov brings both operational and medical knowledge along with extensive international, strategic, and operational experience in the pharmaceutical sector both at senior leadership and board levels. |
| 2022-04-14 | Chief Executive Officer of Galderma SA, a healthcare company focused on dermatology (October 2019 to present) Chief Executive Officer and Board Member of Shire plc (2013 to January 2019) Chief Marketing Officer and Global Head of Strategic Marketing for General & Specialty Medicine at Bayer AG (2010 to 2012) Global President of Pharmaceuticals and OTC at Bausch & Lomb, Inc. (2008 to 2010) Prior to these assignments, held roles of increasing responsibility at, among others, Merck & Co. Inc. and Novartis AG |
| 2023-04-13 | Dr. Ornskov qualified as a Doctor of Medicine at the University of Copenhagen Medical School and earned a Master of Public Health (MPH) from Harvard University School of Public Health and an MBA from INSEAD. |
| 2024-04-12 | Dr. Flemming Ornskov is currently CEO of Galderma (since 2019), a healthcare company focused on dermatology. ... EDUCATION: MD, University of Copenhagen Medical School; MPH, Harvard University School of Public Health; MBA, INSEAD. |
Data sourced from SEC filings. Last updated: 2025-10-12